BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth L. Londoner bought 15,000 shares of BioSig Technologies stock in a transaction dated Monday, May 20th. The stock was purchased at an average cost of $7.78 per share, with a total value of $116,700.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

BSGM opened at $7.01 on Thursday. The company has a current ratio of 10.99, a quick ratio of 10.99 and a debt-to-equity ratio of 0.02. BioSig Technologies Inc has a 52 week low of $3.50 and a 52 week high of $9.97.

BioSig Technologies (NASDAQ:BSGM) last posted its quarterly earnings data on Monday, April 15th. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Equities research analysts forecast that BioSig Technologies Inc will post -1.17 EPS for the current fiscal year.

Several research firms have recently weighed in on BSGM. Zacks Investment Research downgraded BioSig Technologies from a “hold” rating to a “sell” rating in a report on Wednesday. Laidlaw set a $11.00 price objective on BioSig Technologies and gave the company a “buy” rating in a research note on Wednesday, February 20th.

A number of institutional investors and hedge funds have recently bought and sold shares of BSGM. Millennium Management LLC purchased a new stake in BioSig Technologies during the 4th quarter valued at approximately $670,000. Jefferies Group LLC purchased a new stake in BioSig Technologies during the 1st quarter valued at approximately $515,000. Cornerstone Wealth Group LLC purchased a new stake in BioSig Technologies during the 1st quarter valued at approximately $368,000. BlackRock Inc. purchased a new stake in BioSig Technologies during the 1st quarter valued at approximately $365,000. Finally, Cambridge Investment Research Advisors Inc. raised its stake in BioSig Technologies by 49.8% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 90,000 shares of the company’s stock valued at $553,000 after acquiring an additional 29,922 shares during the last quarter. 4.33% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “BioSig Technologies Inc (BSGM) CEO Kenneth L. Londoner Acquires 15,000 Shares” was published by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2019/05/23/biosig-technologies-inc-bsgm-ceo-kenneth-l-londoner-acquires-15000-shares.html.

BioSig Technologies Company Profile

BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.

See Also: Growth Stocks

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.